The potential survival gain and cost-effectiveness of circulating tumor DNA-guided treatment switching in advanced non-small cell lung cancer: A simulation modeling study
{{output}}
Objective: Circulating tumor DNA (ctDNA) has emerged as a minimally invasive approach to assess treatment response in cancer. While ctDNA response has been associated with greater survival outcomes, the clinical benefit and econo... ...
